New combo therapy targets hard-to-treat blood cancers in early trial
Disease control
Recruiting now
This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…
Phase: PHASE1 • Sponsor: Umoja Biopharma • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC